Public Growth Company Saluda Medical has recently IPO'ed and raised significant funding, signaling strong investor interest and capacity for expansion. This presents a sales opportunity to engage during post-IPO growth phases, align solutions with their scale-up plans, and target expansion into new markets or product lines.

US Launch Momentum Recent US commercial launches of EVA sensing tech with Evoke SmartLoop indicate active US market expansion and readiness to adopt advanced neuromodulation technology. Focus on establishing trials, physician training, and reimbursement strategy support within the US to capitalize on this momentum.

Revenue Trail Quarterly revenue growth shows a notable uplift to around twenty-seven million with a near-term trajectory upward. This suggests capacity for upsell opportunities in existing hardware and sensing platforms, as well as bundled service offerings to consolidate revenue streams.

Innovation Edge The world’s first pulse to pulse Closed-Loop SCS system positions Saluda as a tech leader in neuromodulation. Sales dialogue should emphasize differentiated clinical outcomes, data integration capabilities, and long-term support agreements for maintenance and upgrades.

Strategic Partnerships Active collaboration and events participation (e.g., NANS 2025) indicate openness to partnerships and clinical validation. Target opportunities for strategic alliances, joint studies, and co-marketing with hospitals, research centers, and device distributors to accelerate adoption.